Listing 3.07 Bronchiectasis in 2026: The Three-Hospitalizations-in-12-Months Rule, the 30-Day Separation and 48-Hour Duration Tests, and How Imaging Documents the Underlying Disorder

By Anthony Albert, Benefits Research Director, Disability Exchange · Published July 14, 2026

Bronchiectasis is one of those chronic lung diseases where the day-to-day picture doesn't always match the medical file. You might be functional between flares. You might do fine at rest. Then an infection hits, mucus plugs won't clear, you cough up blood or you can't breathe, and you're admitted for a week. Then two months later it happens again. Then again. That pattern of severe exacerbations is what Listing 3.07 measures, and if you hit the exact rule, you get approved without needing spirometry, without needing DLCO numbers, without needing to argue functional capacity at all.

The rule is objective and specific. Bronchiectasis documented by imaging, with exacerbations or complications requiring three hospitalizations within a 12-month period, at least 30 days apart, each lasting at least 48 hours including hours in the ED immediately before the admission. That's the whole test. This article walks through every piece, how DDS counts ED hours, what imaging is needed, and two 2026 case walkthroughs of clean 3.07 approvals.

The exact 2026 rule

Here's Listing 3.07 in the current Blue Book, word for word:

3.07 Bronchiectasis (see 3.00K), documented by imaging (see 3.00D3), with exacerbations or complications requiring three hospitalizations within a 12-month period and at least 30 days apart (the 12-month period must occur within the period we are considering in connection with your application or continuing disability review). Each hospitalization must last at least 48 hours, including hours in a hospital emergency department immediately before the hospitalization.

Break that down. Five pieces:

1. You have bronchiectasis documented by qualifying imaging.
2. You've had three hospitalizations for exacerbations or complications of the disease.
3. All three occurred within a 12-month period that falls within the review window for your claim.
4. The admissions are separated by at least 30 days.
5. Each admission lasted at least 48 hours, counting ED time immediately before the inpatient admission.

Miss any of these and 3.07 doesn't apply. Meet all five and DDS should approve on the initial medical review with no need for functional capacity assessments or vocational analysis.

What SSA means by bronchiectasis

SSA's definition in Section 3.00K is direct. Bronchiectasis is a chronic respiratory disorder characterized by abnormal and irreversible dilation of the airways below the trachea. The dilated airways collect mucus, which becomes a breeding ground for bacteria. That leads to recurrent infections, progressive airway damage, and eventual scarring.

Common causes include:

• Cystic fibrosis (CF): the classic cause, though CF is now diagnosed and treated earlier so severe bronchiectasis presents later in adulthood than it used to
• Non-CF bronchiectasis: the more common form in adults, often idiopathic or post-infectious (childhood pneumonia, tuberculosis, aspiration, immune deficiency)
• Primary ciliary dyskinesia (PCD): genetic disorder causing impaired mucociliary clearance
• Immunoglobulin deficiency: common variable immunodeficiency (CVID) and other primary immunodeficiencies
• Rheumatologic disease: rheumatoid arthritis, Sjogren's, inflammatory bowel disease can all cause secondary bronchiectasis
• Allergic bronchopulmonary aspergillosis (ABPA) in asthmatics and CF patients
• Nontuberculous mycobacterial (NTM) infection: especially Mycobacterium avium complex, increasingly common

SSA doesn't require any specific underlying cause. What matters is the imaging-confirmed diagnosis plus the hospitalization pattern.

The imaging requirement

Section 3.00D3 spells out the imaging SSA accepts. For bronchiectasis, that means:

• High-resolution CT of the chest (HRCT): the gold standard. HRCT shows the dilated, thickened bronchi with clarity that plain CT and chest X-ray can't match. If your case involves 3.07, you need HRCT documentation.
• Chest CT (non-HRCT protocol): can also document bronchiectasis if the findings are described clearly by the radiologist.
• MRI: less common but acceptable when performed.

Chest X-ray alone is not sufficient. Plain films can suggest bronchiectasis (tram tracks, ring shadows) but they miss mild-to-moderate disease and don't reliably show the extent. If your file has only chest X-rays, request HRCT from your pulmonologist. Any pulmonology or infectious disease specialist managing bronchiectasis should already have HRCT ordered.

What counts as an "exacerbation or complication"

SSA's regulation gives examples: acute bacterial infections, increased shortness of breath, coughing up blood. In clinical terms:

• Acute pulmonary exacerbation: increased cough, sputum production, worsening dyspnea, low-grade fever, and lab evidence of infection (elevated WBC, positive sputum culture) requiring IV antibiotics.
• Hemoptysis: coughing up blood, especially massive hemoptysis (>200-500 mL over 24 hours), which is a medical emergency in bronchiectasis and often requires bronchial artery embolization.
• Pneumonia: new consolidation on imaging, often superimposed on baseline bronchiectatic changes.
• Respiratory failure: hypoxic or hypercapnic failure requiring oxygen escalation, BiPAP, or intubation.
• NTM flare: worsening mycobacterial infection requiring IV therapy or antibiotic regimen changes.
• Pulmonary hypertension complication: right heart strain from chronic hypoxia.

The admission diagnosis matters. "Acute exacerbation of bronchiectasis" or "bronchiectasis with pneumonia" or "hemoptysis due to bronchiectasis" are all clear. If admits are coded as "COPD exacerbation" or "asthma exacerbation" without linking back to underlying bronchiectasis, DDS may not count them. Your pulmonologist and hospitalist should make the bronchiectasis link explicit in discharge summaries.

The 30-day separation rule

Three admissions in 12 months isn't enough. Each pair of admissions must be at least 30 days apart. This rule exists to prevent overlapping crises being counted as multiple admissions.

How to count:

• Admission 1 discharge date: January 10
• Admission 2 admission date: February 12 (33 days later, qualifies)
• Admission 2 discharge date: February 18
• Admission 3 admission date: April 3 (44 days after admission 2's admission date, qualifies)

The 30 days runs between admissions, not between discharge and next admission. SSA counts from admission date to admission date. If you're admitted twice for the same problem within 30 days (readmission for the same infection), those may count as one admission, not two.

The 48-hour rule and ED time

Each of the three admissions must last at least 48 hours. Here's the key nuance: ED time counts if it's immediately before the inpatient admission.

Example that qualifies:

• ED arrival: Monday 6:00 PM
• Admitted from ED to inpatient: Tuesday 4:00 AM (10 hours in ED)
• Discharge from inpatient: Wednesday 3:00 PM (35 hours inpatient)
• Total: 45 hours. Doesn't quite meet 48.

Example that qualifies:

• ED arrival: Monday 6:00 PM
• Admitted from ED to inpatient: Tuesday 4:00 AM (10 hours in ED)
• Discharge from inpatient: Wednesday 8:00 PM (40 hours inpatient)
• Total: 50 hours. Meets the rule.

Example that does NOT qualify:

• ED visit Monday, discharged home same day
• Return to ED Wednesday, admitted from that visit
• Wednesday ED counts. Monday ED does not (there was no immediate transition to inpatient).

Observation admissions are murky. Some hospitals put patients in "observation" status rather than full inpatient. SSA hasn't definitively said observation counts for 3.07. Practically, if the observation stay was 48+ hours and clinically indistinguishable from inpatient care (IV antibiotics, respiratory therapy, monitoring), argue for it to count. Have your pulmonologist state in a letter that the care level was the same regardless of billing status.

The 12-month window rule

All three hospitalizations must occur within the same 12-month period, and that 12-month window must fall within the period under review for your claim.

For initial applications, the review period generally starts 12 months before your alleged onset date and continues through the DDS decision. That gives you a wide range. If you had admissions in March 2024, September 2024, and January 2025, that spans 10 months and would meet 3.07 for a 2025 application. If you had admissions in March 2023, November 2023, and December 2024, that spans 21 months and doesn't qualify for 3.07 (though other paths may work).

For continuing disability review, the 12-month period looks at recent hospitalizations. If your disease has stabilized on maintenance therapy (inhaled antibiotics, airway clearance) and you haven't had three admissions in the last year, you may no longer meet 3.07 even though the underlying bronchiectasis is unchanged. In that case, alternative evaluation under Listing 3.02 (chronic respiratory disorders based on PFT results) or a medical-vocational assessment applies.

Documentation checklist that meets 3.07

1. HRCT chest report with radiologist interpretation confirming bronchiectasis, extent (localized vs diffuse), and any complicating features (mucus plugging, mycetoma, etc.).
2. Pulmonology clinic notes documenting the diagnosis, underlying cause (if known), and treatment plan.
3. Discharge summaries from all three qualifying admissions, each stating admission date, discharge date, ED arrival time (if applicable), diagnosis, treatment, and clear linkage to bronchiectasis.
4. Sputum culture results from each hospitalization showing the responsible organism (Pseudomonas, Staph aureus, NTM, Haemophilus, etc.).
5. Antibiotic records showing IV therapy during each admission.
6. Pulmonology attestation letter explicitly listing the three qualifying admissions with dates, durations, and connection to bronchiectasis.
7. Recent PFTs (spirometry, DLCO) for context, even though 3.07 doesn't require specific numbers. If your FEV1 is below 3.02 thresholds, you may meet both listings.

Worked case A: Elena, 44, Miami FL, non-CF bronchiectasis with Pseudomonas

Worked case B: Tomas, 58, Denver CO, cystic fibrosis with NTM co-infection

What happens if you don't meet 3.07

Not everyone with bronchiectasis has three admissions in 12 months. That's actually a high bar. Many patients are managed outpatient with airway clearance, inhaled antibiotics (tobramycin, aztreonam), oral macrolide prophylaxis (azithromycin), and periodic PICC lines for IV antibiotics at home.

If you don't meet 3.07, alternate paths include:

1. Listing 3.02 Chronic respiratory disorders: if your FEV1 or DLCO falls below the age/height/gender-adjusted thresholds in the tables. Severe bronchiectasis with FEV1 under 30-40% predicted often meets 3.02.
2. Listing 3.09 Chronic pulmonary hypertension: if bronchiectasis has led to pulmonary hypertension with mPAP over 40 mm Hg by right heart catheterization.
3. Medical-vocational allowance: if you don't meet any listing but your combined functional limitations (chronic dyspnea, need for airway clearance, medication side effects, fatigue, infection risk, activity restrictions) prevent sustained substantial gainful work. This is the residual path for patients who work between flares but can't hold a schedule.

Common denial reasons and how to counter them

1. DDS says the admissions don't specifically link to bronchiectasis. Counter by producing discharge summaries that name bronchiectasis and by having your pulmonologist write an attestation letter connecting each admission to your underlying disease.
2. DDS excludes admissions that were less than 48 hours inpatient. Counter by adding ED time immediately before the inpatient admission. Request timestamps from the hospital records.
3. DDS counts overlapping admissions as one event. Counter by proving 30-day separation between admission dates (not discharge to next admission, but admission to next admission).
4. DDS says the 12-month window falls outside the claim period. Counter by realigning the review window with your alleged onset date. SSA can consider admissions up to 12 months before onset if they're relevant to establishing severity.
5. DDS accepts observation admissions as insufficient. Counter by having your pulmonologist state that the level of care during observation was identical to inpatient care for those episodes.

2026 treatment context

Current 2026 bronchiectasis treatment includes:

• Airway clearance: chest physiotherapy, high-frequency chest wall oscillation vest, positive expiratory pressure devices, autogenic drainage.
• Nebulized hypertonic saline and mannitol for mucus mobilization.
• Inhaled antibiotics for chronic Pseudomonas: tobramycin (TOBI Podhaler), aztreonam (Cayston), colistimethate.
• Oral macrolide prophylaxis: azithromycin three times weekly for reducing exacerbation frequency.
• IV antibiotics for acute exacerbations: chosen based on sputum culture results.
• NTM therapy: for MAC, standard regimen includes clarithromycin or azithromycin, ethambutol, and rifampin; refractory cases may add amikacin liposomal inhalation suspension (Arikayce).
• CFTR modulators for CF-related bronchiectasis: ivacaftor, elexacaftor/tezacaftor/ivacaftor for eligible mutations.
• Bronchial artery embolization for recurrent massive hemoptysis.
• Lung transplant in end-stage disease.

Aggressive treatment reduces exacerbation frequency, which paradoxically can move some patients out of 3.07 eligibility as their disease stabilizes. That's not necessarily bad news; it just means the case may need to shift to medical-vocational analysis at continuing review.

State pages and related listings

• Florida SSDI resources
• Colorado SSDI resources
• California SSDI resources

• Listing 3.14 Respiratory Failure SSDI 2026
• Listing 14.03 Systemic Vasculitis SSDI 2026

Frequently asked questions